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46 Inconclusive CF diagnosis in Neonatal Screening
C. Colo´n1, P. Ran˜a-Dı´ez2, A. Solar3, C. Soler4, L. Garcı´a3, R. Reparaz3,
A. Ruiz4, J. Ramos4, M. Tabare´s5, P. Pavo´n1, R. Cabanas1, J.R. Alonso-
Ferna´ndez1, A. Carracedo2, F. Barros2, J.M. Fraga1. 1Pediatrı´a, Complexo
Hospitalario Universitario de Santiago. Universidade de Santiago, Santiago de
Compostela, Spain; 2F.P. Galega de Medicina Xeno´mica, Santiago de Compostela,
Spain; 3C.H. Universitario de A Corun˜a, A Corun˜a, Spain; 4C.H. Universitario
de Vigo, Vigo, Spain; 5C.H. de Ourense, Ourense, Spain.
We started the neonatal screening for CF in 2003. Our protocol implies the IRT-
DNA determination. All samples with an IRT level higher than the cut-off value
(70 ng/mL) are checked for mutation analysis using a multiplex MALDI-TOF MS
assay developed by ourselves and adapted to our speciﬁc population (including all
the INNO-LIPA mutations) screening simultaneously more than 180 mutations.
So far, we have analyzed 128,465 newborns and we have diagnosed 16 cases of
cystic ﬁbrosis with a neonatal prevalence of 1:8,000. Other 7 cases were labelled
as uncertain cystic ﬁbrosis (one mutation associated with CF and other one with
uncertain clinical signiﬁcance), 63 cases of carriers and 7 cases with polymorphisms
with not conclusively clinical signiﬁcance.
The F508del was found in 14 of 16 cases of cystic ﬁbrosis (6 cases of them were
F508del homozygous). The allelic frequency was 20 with F508del; 2 with R1162X,
711+1G→T, L206W; and one with V232D, E588V, 2176InsC, 2184insA, R117H,
R334W. All of them presented high sweat chloride levels except one baby with
F508del/R117H mutations.
In 7 cases we found two mutations but only one of them associated to cystic ﬁbrosis
in literature. All of them with inconclusive sweat test results or negative. Those
cases were F508del/D1152H, F508del/V562I, F508del/Y1014C, D1270N/R74W,
2184insA/G576A-R668C, G576A/G1069R and G551D/Y1014C.
We conclude that those cases must be followed to clarify the future possible clinical
signiﬁcance.
47 CF Diagnosis Announcement Practices following a neonatal
screening in France
L.J. Gue´ganton1, G. Minguet2, C. Langeard3, C. Faquet4, P. Cam4, P. Lombrail5,
G. Rault1. 1National CF Reference Center, Nantes, France; 2Ecole des Mines,
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Bordeaux, France; 4University, Nantes, France; 5Medical Health, Evaluation and
Public Health Pole, Nantes, France
In order to improve the quality of care, it was necessary to undertake an evaluation of
the implementation of the CF diagnosis announcement recommendations published
by the French CF Association.
Objectives: (1) establish an inventory of the declared practices with a questionnaire
in all French concerned centers to collect practices in connection with recommen-
dations, (2) check conﬂicts between practices and recommendations and check
facilitating or limiting factors with discussions (focus group – all the team – and
individual interviews – representative of every implied profession) in some centers
according to a classiﬁcation of practices.
Main perspectives: develop improvement actions and other works on announce-
ment in CF, even in other pathologies.
Results: Today, we can expose the principal results of the questionnaires analysis
(response rate: 34 of 37 centers, 92%), namely: the practices meeting the recom-
mendations; the practices less conform to the recommendations and the thematics
requiring more investigations. Results also show that age of centers, annual number
of announcements and internal organization are factors explaining differences in
practices. So, 3 groups of centers could be identiﬁed: “historic” centers (screening
practicing since the 80’s); “high practice” centers (practicing screening since few
years, but for more than 4 announcements per year); “low practice” centers.
Supported by: Fondation de France; Vaincre La Mucoviscidose.
48 Comparing six countries experience of newborn screening for CF
J. Cowlard1, S.B. Carr1, C.S. Pao1. 1Paediatric Respiratory Medicine, Barts and
the London Children’s Hospital, London, United Kingdom
Introduction: London introduced newborn screening for CF in July 2007. Many
countries now screen for CF but there is variation in care and no international
pathway or standards of care.
Method: 8 Paediatric CF centres, in 6 countries were visited, looking at screening
services, hospital & community professionals. All stages along the pathway from
obtaining bloodspots to early management from diagnosis were examined.
Results: 8 centres were visited, each with 100–330 patients. 1−32 CFTR mutations
are tested for at screening. Different health professionals are responsible for giving
initial screening results to families; in 2 centres it is the CF CNS&HV, in 2 centres
it is the Paediatrician and in the remaining 4 centres results are given by either
HV alone, GP, Genetic Counselor or Lead Maternity Carer. For all centres, families
are offered CF team review within 24 hours and ﬁrst contact with the CF team is
with CF CNS & Consultant. Pancreatic enzymes are started at the ﬁrst contact in
all centres.4/6 countries offer outpatient CF education programmes to well infants
and 2/6 offer inpatient programmes. 7/8 centres offer CF CNS home visits post
diagnosis. Problems identiﬁed were CF information & informed consent at the
heelprick test & repeat IRT, who should deliver the screening results, early post
diagnosis management (surveillance, support, professionals involved). Innovative
practices found were parent education DVDs, GP guides to CF and “new” CF baby
clinics.
Conclusion: Due to differences between centres, there is probably no one ideal
pathway. Local constraints include time, resources and for many geographical
distance. It is difﬁcult to establish exactly what “best care” is around screening &
diagnosing CF. Our pathway will continue to be reviewed and revised as necessary
and will involve parents in future planning.
49 Neonatal CF screening (2003–2008) in the Aquitaine region in
France: high probability of a second CFTR gene mutation in
heterozygotes with subnormal sweat tests
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In the French Aquitaine region, 207 174 newborns (nb) were screened for CF from
2003 to 2008. Day-3 (d3) immunoreactive trypsin (IRT) was elevated in 174 nb in
whom the most common CFTR gene mutation analysis was performed. At this stage,
CF (2 CF-causing mutations) was diagnosed in 33 nb, 83 nb were heterozygotes
(het) and 58 had no mutation. Five CF nb presented with meconium ileus (3 of
whom were not screened due to normal IRT). Moreover 2 nb who presented with
clinical signs of CF several months or years later, albeit without elevated IRT on
d3, were considered as false negative CF cases of the screening.
We focused on het nb on d3 with subnormal sweat test (ST) to test mild elevation
of sweat chloride as an indicator for complete screening of CFTR gene in het nb.
Sweat chloride (in duplicate) was measured in 83 het. The majority (n = 69, i.e. 83%)
had low sweat chloride (mean: 9±3mmol/l) and could deﬁnitely be considered as
het. But 11 het nb (13% of het) had moderately but signiﬁcantly increased ST
(mean: 21±3mmol/l; range 15−30) and often at the same time IRT> 100mg/l.
In 9 het nb a complete CFTR gene analysis was performed; and in 8 of these
cases (89%) a second gene variation was detected. This additional variation was:
a CF-causing mutation (n = 4), a CFTR-RD-causing mutation (n = 3), an apparently
neutral nucleotide change (n = 1).
The complete results of CF screening in the Aquitaine region (including those
resulting from complete genotyping for d3 “het” with a subnormal ST and the false
negative CF cases of the screening) indicate an incidence of 1/4228 (n = 49) for
bearers of 2 CFTR gene variations and of 1/4603 (n = 45) for CF children.
